Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6958628 | 0.90 | SLC6A2 (0.66) | SLC6A4SLC6A2SLC6A3CHRM1KCNH2 | |
| SCHEMBL4440722 | 0.89 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3CHRM1KCNH2 | |
| SCHEMBL8936781 | 0.84 | ESRRA (0.43) | SLC6A4SLC6A2SLC6A3CHRM1KCNH2 | |
| SCHEMBL4440290 | 0.84 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3CHRM1KCNH2 | |
| SCHEMBL4440731 | 0.82 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL4442267 | 0.80 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL4441929 | 0.80 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL7769553 | 0.79 | SLC6A2 (0.61) | SLC6A4SLC6A2SLC6A3CHRM1 | |
| SCHEMBL8936811 | 0.79 | HTT (0.61) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL18783678 | 0.77 | MAPT (0.57) | SLC6A4MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | SLC6A4 724/4885SLC6A2 247/4885SLC6A3 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.